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Supplemental Experimental Procedures

RNAi screening
The synthetic lethal RNAi screening was carried out at the High-Throughput Screening Core Facility of MSKCC. The kinome and phosphatome Ambion Silencer Select v4.0 libraries were purchased from Life Technologies and contain 2130 unique siRNAs targeting each of the 710 human kinase genes and 894 unique siRNAs targeting each of the 298 human phosphatase genes. Diluted siRNA were transferred into assay plates at a final concentration of 50 nM. As a reference, we used Silencer Select Negative Control #1 siRNA (4390843) as a negative control and PLK1 siRNA (s449) as the positive control. JIMT1 and HCC1954 cells were seeded and were reverse transfected using Dharmafect-1 at 0.05 µL/well. Next, cells were treated with DMSO or BYL719 1 µM and 7 days after transfection, cell viability was assessed using Alamar blue and Nuclei Count using Hoechst staining and quantified using LEADseeker (GE Healthcare) and INCA2000 (GE Healthcare), respectively. For the hit nomination, the BDA method was used as previously described (Bhinder and Djaballah, 2012) . Briefly, this method comprises 5 steps to analyze and score active siRNA duplexes and genes: (1) active duplex identification, (2) active gene identification, (3) off-target effects filtering, (4) re-scoring, and (5) biological classifications. To identify modulators of BYL719 resistance, active genes were nominated from the active siRNA duplexes using a hit rate per gene (H score) of ≥60. H score is defined as follows:
H score = number of active siRNA duplex total number of siRNA duplexes × 100
Using this approach, 5 genes were identified and the two most active duplexes of each gene were purchased and screened for cell viability and pS6 staining in the presence of BYL719 1 µM. siRNA were from Ambion: PIK3CA (s10520, s10522), MTOR (s602, s603), PDPK1 (s10274, s10275), PAPL (s52890, s52892), and PP1R12A (s935, s937). Confirmation screening was carried out as described above. For pS6 (S240/4) staining, cells were reversetransfected and after 72 hr, they were treated for 4 hr with BYL719 at 1 µM. Next, cells were fixed with 4% Paraformaldehyde in PBS and stained using pS6 (S240/4) antibody from Cell Signaling (2215), followed by Alexa Fluor 488 secondary antibody. Fluorescence was quantified using INCA2000 (GE Healthcare).
Final nomination was performed using the H score described above and genes that sensitized cells to BYL719 and decreased pS6 (S240/4) were selected.
Plasmids and site-directed mutagenesis
The Myc-tagged constructs pCCL-PDK1 WT, KD (K111N), K465E, and L155E were a gift from Dr. Primo and Dr. Gagliardi (University of Turin). pLPCX-HA-SGK1(Δ60) was obtained from Dr. Conzen (The University of Chicago) and was used as a template to subclone the cDNA and generate pdEYFP-SGK1(Δ60) and pLenti7.3-V5-SGK1(Δ60,S422D). The kinase-inactive K127A and constitutively active S422D mutant were generated using PCRbased site-directed mutagenesis. Plasmids expressing Flag-tagged mTOR (26603), TSC1 (8995), TSC2 (8996), RHEB (15888), and HA-S6K (ΔCT, T389E) (8993) were obtained from Addgene. pcDNA3-Flag-TSC2 WT and 5A (S939A, S981A, S1130A, S1132A, T1462A) were a gift from Dr. Manning and were used as a template for the generation of pcDNA3-Flag-TSC2 6A (5A, S1798A) and pcDNA3-Flag-TSC2 6E, respectively. Plasmids encoding for the TSC2 truncation mutants were provided by Dr. Xiong (University of North Carolina at Chapel Hill) and pEGFP-TSC2 was from Dr. Krymskaya (University of Pennsylvania). PDPK1 targeting shRNA pLKO-based vector used in this study was TRCN0000039782, although other clones were also tested. RICTOR-targeting shRNA plasmid was from Addgene (1853). Lentiviral doxycycline-inducible mirE-embedded shRNAs were XhoI/EcoRI cloned into the LT3GEPIR vector previously described (Fellmann et al., 2013) . Briefly, this all-in-one vector contains the puromycin resistance and the reverse transactivator (rtTA3) under the control of the constitutive phosphoglycerate kinase (PGK) promoter. The shRNA and the fluorescent marker GFP are expressed under the control of the Tet-responsive element promoter (T3G). Control shRNA was a hairpin designed against the Renilla reniformis luciferase. SGK1 shRNA was chosen experimentally based on five different hairpins. The sequence targeting the exon 5 provided the most robust results.
REN shRNA:
5'-TGCTGTTGACAGTGAGCGCAGGAATTATAATGCTTATCTATAGTGAAGCCACAGATGTATAGATAA GCATTATAATTCCTATGCCTACTGCCTCGGA-3' SGK1#282 shRNA:
5'-TGCTGTTGACAGTGAGCGCAGAAGTGTTCTATGCAGTCAATAGTGAAGCCACAGATGTATTGACTG CATAGAACACTTCTTTGCCTACTGCCTCGGA-3' All constructs were validated by Sanger sequencing.
Cells and lentiviral production
All cell lines were obtained from ATCC except for JIMT1 (AddexBio), used at low passages, and maintained at 37°C in a 5% CO 2 atmosphere in the recommended culture media. HCT116 PDPK1 -/-and PDPK1 +/+ cells were a gift from Dr. Mills (MD Anderson) and were originally generated by Dr. Vogelstein's laboratory (Johns Hopkins University) (Ericson et al., 2010) . For lentiviral production, 293T cells were seeded in 10-cm plates, transfected with pCMV-VSVG, pCMV-dR8.2, and the plasmid of interest using FuGene HD (Promega). Viruses were collected 72 hr post-transfection, filtered through a 0.45 µm filter (Millipore), and recipient cells were infected twice using viral supernatants supplemented with 8 µg/µL of polybrene (Sigma). Transduced cells were selected using puromycin (2 µg/mL) or Fluorescence Activated Cell Sorting (FACS) for the pCCL and pLenti7.3 vectors, which contain EGFP as a selectable marker.
Reagents, cell viability and apoptosis BYL719 and MK2206 were obtained from the Stand Up to Cancer (SU2C) pharmacy. GSK2334470 and Staurosporine were purchased at Selleckchem. SGK1-inh was a gift from M. Nazare and N. Halland. All drugs were dissolved in DMSO for in vitro experiments. Cell viability was measures using the MTT assay. Briefly, 5000 cells were seeded in 96 well plates, treated for 6 days, and assayed using 0.25% MTT (Sigma) and 50 mM sodium succinate (Sigma) solutions for 3 hr. Formazan crystals were dissolved with DMSO and absorbance was measured at 570 nm of wavelength. For Caspase 3/7 activity, the Caspase-Glo® 3/7 Assay kit from Promega was used following manufacturer's instructions. The caspase inhibitor zVAD-fmk was used to inhibit apoptosis in cells and was also obtained from Promega.
Immunoblot, immunoprecipitation, and kinase assay For western blot analysis, proteins were extracted in RIPA buffer supplemented with protease and phosphatase inhibitors (Roche). Protein lysates were separated using SDS-PAGE gels and transferred to a PVDF membrane. Then, membranes were probed using specific antibodies. PDK1, pAKT (S473), pAKT (T308), pS6K (T389), pS6 (S240/4), pS6 (235/6), p4EBP1 (S65), PARP, Actin, pRSK (S227), cleaved Caspase 3, pFOXO1/3 (T24/T32), SGK1, SGK2, SGK3, pNDRG1 (T346), NDRG1, Flag, HA, TSC2, pAcetyl-CoA Carboxylase (Ser79), pbetaCatenin (S33/7), pERK1/2 (T202/Y203), pRSK (T359), pTSC2 (S939), TBDC1D7, TSC1, and phospho-RXRXX(S/T) were from Cell Signaling Technology (CST). For S6K T229 phosphorylation detection we used pPKC (pan) (γT514) (9379) from CST, as previously reported (Garcia-Martinez and Alessi, 2008) . The SGK1 and AKT antibodies for endogenous immunoprecipitation were raised in sheep by the Division of Signal Transduction Therapy (DSTT) at the University of Dundee and affinity-purified against the indicated antigens: anti-AKT1 (S695B, third bleed; raised against residues 466-480 of human Akt1: RPHFPQFSYSASGTA), anti-SGK1 antibody (S062D, third bleed, raised against recombinant SGK1 protein (DU35257). For endogenous co-immunoprecipitation of SGK1 and TSC2, we employed the S062D sheep antibody in 10 mg of JIMT1 lysate and TSC2 was recognized using the CST rabbit antibody with a secondary conformational specific antibody (Clean Blot from Thermo). For immunoprecipitation assays, 293T cells were transiently transfected with appropriate plasmids and 24 hr posttransfection, cells were washed in cold PBS and lysed using NP-40 buffer (150 mM NaCl, 10 mM Tris pH 8, 1% NP-40, 10% glycerol). Lysates were rotated at 4°C for 4 hr with EZview™ Red ANTI-FLAG® M2 or ANTI-HA agarose beads (Sigma) and washed three times using NP-40 buffer. For in vitro kinase assay, immunoprecipitated
The structure of SGK1 kinase is only available in its inactive form, with missing structural information such as the coordinates of the αC helix. We constructed the 3D structures of SGK1 kinase both in its active and inactive forms using comparative modeling methods based on homology. The templates used were the available crystal structure of SGK1 kinase in the inactive state (PDB: 2R5T) (Zhao et al., 2007) , high-resolution crystal structure of the kinase domain of AKT (55% homology) in its active (PDB: 1O6K) (Yang et al., 2002a) and inactive (PDB: 1GZN) (Yang et al., 2002b) states. The program Modeller (version 9.12) (Sali and Blundell, 1993) was used for the generation of homology models. Several models were generated and the models with the best physicochemical properties were further refined using all atom molecular dynamics (MD) simulations. The 3D structures of SGK1-inh and ATP were built using the Maestro module and minimized using the Macromodel module, employing the OPLS-2005 force field, in the program Schrodinger 9.0. The minimized SGK1 inhibitor and ATP were docked into the binding pockets of SGK1 kinase models with Glide (Friesner et al., 2004) using standard docking protocols (Kannan et al., 2015) . Refinement of the docked models of SGK1-inhibitor and SGK1-ATP complexes were carried out using MD simulations under the Sander module of the program Amber14. The partial charges and force field parameters for SGK1 inhibitor and ATP were generated using the Antechamber module in Amber. All atom versions of the Amber 03 force field (ff03) (Duan et al., 2003) and the general Amber force field (GAFF) (Wang et al., 2004) were used for the protein and the inhibitors respectively. All the simulations were carried out at 300 K using standard protocols (Kannan et al., 2015) . Three independent MD simulations (assigning different initial velocities) were carried out on each equilibrated SGK1-ATP and SGK1-inhibitor structure for 100 ns each, with conformations saved every 10 ps. Simulation trajectories were visualized using VMD (Humphrey et al., 1996) and figures were generated using Pymol. The binding free energies (enthalpic components), energy decompositions (to identify "hot spot" residues) and computational alanine scans (of the "hot spot" residues) were calculated using the MMPBSA (Molecular Mechanics Poisson-Boltzmann Surface Area) methodology (Kannan et al., 2015) .
DNA methylation quantification
For DNA methylation analyses, bisulfite conversion of 500 ng of genomic DNA was performed using the EZ DNA Methylation Gold kit (Zymo Research, Orange, CA, USA) following the manufacturer's indications. For bisulfite sequencing, specific primers were designed to amplify the annotated promoter region using the MethylExpress program (Applied Biosystems) (Fw-AATTTTAGAATTTGGAAGAGGA and Rv-ACAACCTTAAATTAAACCCAAA), and a minimum of eight single clones was interrogated for each cell line. In order to quantify the absolute levels of DNA methylation on CpG sites in the proximity of the transcription start site of SGK1 we carried out pyrosequencing on bisulfite-treated DNA using specific primers designed with the PyroMark Assay Design Software (Qiagen, version 2.0.01.15) (Fw-GAGGGAGAGGTTAGGAATGT, Rv-CCCTCCCTTCRCTTATTACCTCCTCAC and Seq-TTTTGAAGTAATTTTTGAGAATATT). Pyrosequencing reactions and quantification of DNA methylation values were performed in a PyroMark Q96 System version 2.0.6 (Qiagen) including appropriate controls. As previously described, SGK1 DNA methylation levels were categorized into three groups. DNA methylation values in the first group (<33%) were defined as low DNA methylation, and high DNA methylation was assigned to values on the two top groups (>33%).
FRET
For FRET experiments, HeLa cells were seeded in chambered coverglass and transfected with 0.5 µg of EGFP Donor plasmid, 0.5 µg of EYFP Acceptor plasmid, or both constructs. 16 hr post-transfection cells were imaged with a Leica TCS SP8 microscope using the established parameters for Donor (Ex: 458 nm laser at 15%; Em: 466-501 nm) and Acceptor (Ex: 528 nm laser at 3%; Em: 555-600 nm). FRET efficiency was calculated using the following equation as described in (van Rheenen et al., 2004) :
Where FRET, EGFP and EYFP refers to the FRET, Donor and Acceptor channels respectively. The corrections factors were α=0.01; β=0.37; γ=0.31; δ=0.02, where α corrects for acceptor cross-excitation crosstalk (α=Donor/Acceptor), β corrects for donor crosstalk (β=FRET/Donor), γ corrects for acceptor cross-excitation (γ=FRET/Acceptor), and δ corrects for FRET crosstalk (δ=Donor/FRET). Mock-transfected cells were used to calculate the background threshold level (background intensity mean + 4 Standard deviation).
TMA and patients
Formalin-fixed paraffin-embedded (FFPE) tissue blocks from primary invasive breast carcinomas were used to construct the TMA reported in this study. A certified pathologist (E.B.) microscopically examined hematoxylin and eosin-stained sections of all the tumors and selected representative areas, excluding foci of ductal carcinoma in situ and tumor necrosis. All carcinomas were represented in the TMAs in triplicate 0.6-mm cores. An Automatic Tissue MicroArrayer (ATA-27, Beecher Instruments Inc) was used to construct TMAs from a total of 273 breast invasive carcinomas. This comprised clinically and pathologically confirmed triple-negative breast cancer patients (138), ER/PR receptor-positive breast cancer patients (68), and HER2-positive cancer patients (67). Tumor were considered ER/PR receptor-positive if >10% of neoplastic cells showed nuclear positivity. Cases with HER-2 staining intensity of 3+ were considered positive, whereas those with 2+ staining intensity of HER2 were further evaluated by ERBB2 FISH using the PathVision HER2 probe Kit (Abbott Laboratories), and scored as positive if the HER2/Cep17 ratio was 2.2 or greater. 5-µm thick TMA sections were stained for pNDRG1 (T346) following the protocol described above. Based on the observed staining across the different samples, cases were scored as High expression when pNDRG1 staining intensity of 2+ was found >20% of the neoplastic cells. Intermediate staining represented tumors that had 1+ staining intensity in >10% of the neoplastic cells. For the study of patients treated with the PI3Kα inhibitor BYL719, pre-treatment biopsy FFPE blocks from patients enrolled in the clinical trial NCT01870505 conducted at MSKCC were used for IHC as described above. For the selection of the patients, PIK3CA and other tumor genomic drivers were analyzed using MSK-IMPACT (Cheng et al., 2015) . Only patients that did not exhibit toxicity during the trial, harbored hot-spot mutations in PIK3CA, and
